A Synopsis of Serum Biomarkers in Cutaneous Melanoma Patients by Vereecken, Pierre et al.
Hindawi Publishing Corporation
Dermatology Research and Practice
Volume 2012, Article ID 260643, 7 pages
doi:10.1155/2012/260643
Review Article
A Synopsis of Serum Biomarkers in
CutaneousMelanoma Patients
Pierre Vereecken,1 Frank Cornelis,2 Nicolas Van Baren,3
Val´ erie Vandersleyen,1 andJean-Franc ¸oisBaurain2
1Department of Dermatology, Centre Hospitalier Valida and Cliniques Universitaires Saint-Luc, B-1082 Brussels, Belgium
2Department of Medical Oncology, Cliniques Universitaires Saint-Luc, Brussels, Belgium
3Brussels Branch, Ludwig Institute for Cancer Research, Brussels, Belgium
Correspondence should be addressed to Pierre Vereecken, pierre.vereecken@uclouvain.be
Received 12 July 2011; Accepted 28 September 2011
Academic Editor: G´ erald E. Pi´ erard
Copyright © 2012 Pierre Vereecken et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Many serum biomarkers have been evaluated in melanoma but their clinical signiﬁcance remains a matter of debate. In this paper,
a review of the serum biomarkers for melanoma will be detailed and will be discussed from the point of view of their practical
usefulness. The expression of biomarkers can be detected intracellularly or on the cell membrane of melanoma cells or noncancer
cells in association with the melanoma. Some of these molecules can then be released extracellularly and be found in body ﬂuids
such as the serum. Actually, with the emergence of new targeted therapies for cancer and the increasing range of therapeutic
options, the challenge for the clinician is to assess the unique risk/response ratio and the prognosis for each patient. New serum
biomarkers of melanoma progression and metastatic disease are still awaited in order to provide eﬃcient rationale for followup
and treatment choices. LDH as well as S100B levels have been correlated with poor prognosis in AJCC stage III/IV melanoma
patients. However, the poor sensitivity and speciﬁcity of those markers and many other molecules are serious limitations for their
routine use in both early (AJCC stage I and II) and advanced stages of melanoma (AJCC stage III and IV). Microarray technology
and proteomic research will surely provide new candidates in the near future allowing more accurate deﬁnition of the individual
prognosis and prediction of the therapeutic outcome and select patients for early adjuvant strategies.
1.Introduction
The incidence of cutaneous malignant melanoma (CMM) is
still increasing in the western world despite early detection
and prevention campaigns. Patients are mostly young and
late diagnosis, which means thicker tumors (thicker than
1mm, or Breslow index ≥1mm: the Breslow index is the
measurement in mm of the vertical thickness of the primary
tumor) and/or involvement of regional lymph nodes, causes
a greater risk of developing a disseminated disease. CMMs
usually progress from an in situ proliferation to a radial
growth pattern, and then to a vertical growth phase. This
vertical growth phase represents a key event for the cell
spread, since it allows the cells to migrate deeply in the
dermis, in the lymphatics, and the bloodstream.
In the 7th revision of the American Joint Committee
on Cancer (AJCC) for melanoma staging and classiﬁcation
(2009), patients can be divided in four stages, from stage I
and II (local disease) to stage III (locoregional disease) and
stage IV (metastatic disease). In this classiﬁcation, the only
marker which has been incorporated for clinical use is lactate
dehydrogenase (LDH) since elevated serum LDH has been
shown in multivariate analysis to be an independent and
highly signiﬁcant predictor of survival even after accounting
for site and number of metastases.
Surgery remains the mainstay of the melanoma treat-
ment. Actually, the major concern after the diagnosis by
primary surgery or primary excision is to know whether
this cancer has already metastasized or not. Indeed many
arguments emphasize that early detection of melanoma
metastasis could improve the prognosis of patients, at least
for a part of them.
High-risk melanoma patients can be deﬁned by a 50%
risk of relapse despite initial optimal surgical treatment.2 Dermatology Research and Practice
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Figure 1: The process of metastasis is theconsequence of migration
of melanoma cells from the primary lesion, to locoregional and
distant body sites via the lymphatic circulation and the blood-
stream. Sentinel lymph node is the ﬁrst draining lymph node
in which melanoma cells may ﬁnd a suitable environment and
survive, leading to micro- or macrometastasis. If the cells spread
hematogenously, distant metastasis will appear.
This group of patients should be carefully followed and if
possible treated by eﬃcient adjuvant therapeutic strategies.
Interferon-α and more recently ipilimumab have been pro-
posed as adjuvant treatments but their eﬀect on survival
is still a matter of debate. To date no predictive factor of
response has been described.
The process of metastasis involves the spread of neoplas-
tic cells to locoregional or distant body sites via lymphatic
vessels and/or bloodstream. In the case of melanoma,
circulating cells may ﬁnd a suitable microenvironment in
the ﬁrst draining lymph node, known as the sentinel lymph
node, in other lymphnodes or in distant organs, leading to
secondary tumor growth (Figure 1). Melanoma may spread
to almost all organs, with predilection for lymph nodes, liver,
lungs, brain, and bones. Understanding the biology and the
mechanismofmetastasisprovidesnewmoleculartargetsand
may help us to discover new biomarkers.
When metastatic disease is conﬁrmed late and surgery
can no longer be chosen, therapeutic options are limited
and give disappointingly low responses. These options
include speciﬁc or nonspeciﬁc immunotherapy, chemother-
apy, radiotherapy, radiosurgery, radiofrequency ablation.
2. Towards the Deﬁnition of a Biomarker in
CutaneousMalignantMelanoma?
Biomarkers can be divided into diagnostic markers for
screening and prognostic markers, which can be used once
thecancerhas been diagnosed and predictive markers, which
should predict the likely response to a treatment.
Cancer biomarkers include molecular tools such as
proteins, peptides, DNA, mRNA, or processes which can be
measured in a given cancer, with speciﬁc quantitative and
qualitative tools. These markers can be found in tissues, cells,
and/or body ﬂuids. In addition viable melanoma cells can
also be found in the peripheral blood of melanoma patients.
The discussion will be limited here to serum biomarkers in
melanoma patients.
The ideal serum biomarker should be a molecule detec-
tion which in the blood allows diagnosis of a growing tumor
inapatient. Thebiomarkermust exhibit suﬃcientsensitivity
and speciﬁcity in order to minimize false negative and false
positive results. The sensitivity refers to the proportion of
patients with a conﬁrmed disease who will have a positive
test for a biomarker, while the speciﬁcity can be deﬁned by
the proportion of healthy individuals with a negative test.
Previous studies have shown that many molecules which
may be involved in oncogenesis and cancer spread can
be found in the serum of cancer patients in particular
melanoma patients, but their sensibility and/or speciﬁcity
is still questionable. These molecules can be produced and
secreted or shed into the bloodstream directly by melanoma
cells or indirectly through destruction of melanoma cells
by chemotherapy, immunotherapy, or combined therapy.
Biomarker discovery is a complex research process which
involves scientiﬁc collaboration and data share. Early ap-
proaches rested on clinical and pathological ﬁndings, as
illustratedbytheCEAandthePSAstories,butnowemerging
technologies such as genomics and proteomics have inﬂu-
enced and changed the paradigm.
At this moment no ideal biomarker exists in the
melanoma ﬁeld, and additional markers (combined mark-
ers) provide probably more useful information as shown in
some reports. Routine use of tumor markers is an important
issue because it would allow early detection and deﬁnition of
therapeutic strategy.
In addition, melanoma biomarker research is an open
ﬁeld for the understanding of molecular events in melanoma
progression and should provide new molecular targets for
therapeutic intervention.
Hereafter we detail the most important serum molecules
which have been described as biomarker for CMM.
2.1. Common CMM Biomarkers
2.1.1. Lactate Dehydrogenase (LDH). As already discussed
above, this enzyme has been considered as the main serum
parameter in metastatic melanoma patients and identiﬁed as
a“good”biomarkerinmetastaticpatients.Manystudieshave
presented LDH as the most predictive independent factor.
ThisledtoastratiﬁcationintheAmericanJointCommit-
tee of Cancer staging system. Metastatic melanoma patients
with high LDH levels are designated as M1c whatever the site
of metastases.
However, Hamberg et al. [1] recently indicated that in a
series of 53 AJCC stage IV melanoma patients only 38% had
high levels of LDH, suggesting that elevated LDH is not the
ideal marker for this condition. Moreover, in a multivariate
analysis of 64 AJCC stage IV melanoma patients, Hauschild
et al. [2] failed to demonstrate the independent prognostic
value of LDH. It should be also remembered that LDH
dosage can be falsely positive due to haemolysis and other
factors among them hepatitis. Others markers are thus
needed.Dermatology Research and Practice 3
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Figure 2: Survival curves according to serum S100B levels: a S100B
> 0.1μg/dL is a bad prognosis factor (personal data).
2.1.2. C-Reactive Protein (CRP). CRP is a nonspeciﬁc in-
ﬂammatory parameter which might have a role in the
detectionofmelanomaprogression.Thisproteinisproduced
by hepatocytes as a nonspeciﬁc acute phase response of
inﬂammation processes.
High serum CRP levels have been linked to poor prog-
nosis in various neoplasia. In a recent report, Deichmann
et al. [3–5] analyzed the prognostic signiﬁcance of C-
r e a c t i v ep r o t e i n( C R P )c o m p a r e dt oL D Hi nA J C Cs t a g e
IV melanoma patients. With a cut-oﬀ point of 3mg/dL,
serum analysis discriminated between stage IV and nonstage
IV melanoma patients, with a sensitivity of 76.9% and a
speciﬁcity of 90.4%. In another prospective study of 67
patients, Deichmann considered that CRP alone was the
most relevant prognostic parameter [3]. These results are
debated.
2.1.3. S100-β Protein (S100B). S100B protein is a 21-kd
dimeric protein, consisting of two subunits β. This protein is
a member of a 19 proteins family and was ﬁrst isolated from
bovine brain in the mid sixties. S100B protein is expressed
by glial cells and melanocytes and has been shown to be
produced by brain tumors and melanoma.
Roles of S100B are probably multiple and underesti-
mated. It can interact with the p53 tumor suppressor gene
in a calcium-dependent manner.
The serum S100B level is linked to the tumor burden and
reﬂects clinical stage and tumor progression as reported by
some.
Thereis increasingevidencethattime-dependent evalua-
tion of serial blood measurements of S100B is useful in order
to follow melanoma patients (Figure 2); many reports have
shownthatS100Blevelsarecorrelatedwithclinicalstage(the
higher the level, the more advanced the stage) and could be
used to monitor the eﬀectiveness of antitumoral treatment
whatever the type of the treatment (surgical, chemotherapy,
immunotherapy). Retsas et al. [6] have even suggested the
use of S100B instead of LDH in the AJCC staging system
while other authors consider that S100B does not have any
added value when comparing its sensitivity and speciﬁcity to
CRP and LDH.
S100B has probably become the most useful tumor
marker in clinical practice but seems limited to advanced
stage III and stage IV melanoma patients: in stages I and II
S100B does not provide independent prognostic informa-
tion. Currently S100B is not used routinely despite a high
predictive value for the recurrences in this group of patients.
Moreover one should remember that S100B is not
melanoma speciﬁc and that its serum level can be elevated
in healthy subjects, nonmelanoma skin cancer patients, in
neurological disorders, in AIDS, in central nervous system
tumours, and even in various gastrointestinal cancers.
2.2. Novel Molecules Which Can Be Considered as
Possible Biomarkers in CMM
2.2.1. Melanoma Inhibitory Activity (MIA). M I Ai sa1 2k D a
soluble protein, the role of which has been characterized
as an autocrine cell growth inhibitor. It can be expressed
by melanoma cells as well as chondrocytes. The roles of
this protein are multiple as the molecule may modulate
cell growth and cell adhesion. MIA has been shown to
be elevated in the serum of relapsing cases (Elisa test)
and has been described as a useful marker to monitor
melanoma patients after surgery. Some authors considered
that sensitivity of both molecules MIA and S100B is equal.
For some authors neither MIA nor S100B is superior to LDH
and CRP on multiple logistic regression analysis. In children
and pregnant women (after week 38), MIA is increased and
MIA serum measurements should be thus avoided in these
two groups [7].
2.2.2. Galectin-3. Galectin-3 is the member of the family
of lectins which can bind to β-galactosides. Many members
of the galectin family are diﬀerentially expressed in cancer.
Gal-3 is a molecule which contains an NH2-terminal
domain, a COOH-terminal domain, and a collagen-like
long sequence. In melanoma, Gal-3 has been shown to be
overexpressed in malignant melanocytic lesions and also
released in serum of melanoma patients by both melanoma
cells and inﬂammatory cells. Gal-3 has been shown to play
important roles in cell proliferation, cell diﬀerentiation,
cell adhesion, cell migration, angiogenesis, and metastasis.
Thus, Gal-3 deserves close attention, and clarifying the role
of extracellular Gal-3 should help us to understand the
signiﬁcanceofhighserumlevelsofthismoleculeinadvanced
melanoma patients.
2.2.3.Melanoma-AssociatedAntigensandCirculatingMelano-
ma Cells. Malignant transformation of melanocytes causes
changes in gene expression. This leads to the expression of4 Dermatology Research and Practice
Table 1: Melanoma-associated antigens (adapted from Visser et al.
[11]).
Antigen HLA restriction
Oncospermatogonal antigens
MAGE-A1 A∗01, A∗03, A∗24, A∗28, B∗3701,
B∗53, Cw∗0201, Cw∗0301, Cw∗1601
MAGE-A2 A∗0201, B∗3701
MAGE-A3 A∗01, A∗02, A∗2402, B∗3701, B∗44,
DR∗11
MAGE-4 A∗0201
MAGE-A6 A∗3402, B∗3701
MAGE-A10 A∗0201
MAGE-A12 A∗0201
MAGE-B1 A∗0201
MAGE-B2 A∗0201
BAGE Cw∗1601
GAGE-1 Cw∗6
LAGE-1 A∗0201
PRAME A∗24
NY-ESO-1 A∗02, A∗31
DAM-6 A∗02
Melanocytic diﬀerentiation antigens
Tyrosinase A∗01, A∗0201, A∗2402, B∗44,
DRβ1∗0401
MART-1/Melan-A A∗0201, A∗02, B∗4501
Gp100 A∗0201, A∗03, A∗0301, A∗1101,
A∗2402, C∗0802, DRβ1∗0401
TRP-1 A∗31
TRP-2 A∗31, A∗33, A∗0201, C∗0802,
A∗68011
MC1R A∗0201
Mutated antigens
MUM-1 B∗44
CDK4 A∗02
B-catenin A∗24
P15 A∗24
GnT-V A∗02
TPI DRβ1∗0101
Annexin II DRβ1∗0401
CDC27 DRβ1∗0401
Oncogene-derived antigens
HER2/Neu A∗0201
molecules—so called melanoma associated antigens—which
are more or less speciﬁcally associated with the malignant
phenotype (Table 1). Sometimes these MAA can also be
expressed in normal melanocytes but then can be observed
in sequestered sites. These MAAs play important roles
in triggering the antimelanoma immune response. These
antigens have mostly been identiﬁed by immunological
approaches, including in vitro and vivo reactions, and by
serological tests. These antigens can be deﬁned by their
ability to interact with T or Bcells, and peptides derived from
these antigens have been used to induce or sustain a speciﬁc
antimelanomaimmunologicalresponse.Mage-1wastheﬁrst
MAAidentiﬁedbyageneticapproachintheLudwigInstitute
for Cancer Research, Brussels, Belgium and this belongs to
a broad family of at least 12 antigens diﬀerentially expressed
bybenignandmalignantmelanomacells.Immuneresponses
to these genes can be used as markers of disease and/or the
existence of immune competence.
Polymerase chain reaction technique (PCR) is a tech-
nique which allows the detection of 1 tumor cell among 107-
108 cells which is much more precise than light microscopy
with a limit of detection of 1/100 –1/1000. PCR-based tech-
niques rest on an exponential ampliﬁcation of speciﬁc DNA
or RNA molecules. With this technique, the identiﬁcation
of tumor-speciﬁc or tumor-associated genes leads to speciﬁc
detection of tumor cells.
In RT-PCR serum analysis, RNA of the sample is ﬁrst
extracted and reversely transcribed into cDNA (reverse
transcription). A gene of interest is then ampliﬁed thanks to
speciﬁc primers, and isolated on agarose gel, or hybridized
after southern blotting. Sequencing of the product of PCR
c a nb ec a r r i e do u ti no r d e rt oc o m p a r ei tw i t ht h eg e n eo f
interest.
Serum tyrosinase activity or positive tyrosinase RT-PCR
in melanoma patients has been shown to be correlated with
higher risk of relapse, but only 55% of these patients will
experience a clinical relapse [8]. Moreover the speciﬁcity
of this technique has yet to be optimized [9]. When com-
bined with a S-100 assay, Domingo-Domenech showed that
tyrosinase RT-PCR adds valuable prognostic information in
patients with S-100 < 0.15μg/l, even if this team showed that
S-100 had a higher predictive value.
Curryetal.[10]havesuggestedthatRT-PCRdetectionof
tyrosinase and MART-1 (Melanoma Antigen Recognized by
T cells-1) positive circulating melanoma cells can be useful
to determine a subgroup of patients with increased risk of
metastasis.
2.2.4. Melanin-Related Metabolites. 5-S-cysteinyldopa is a
precursor of phaeomelanin and is produced by both melan-
ocytes and melanoma cells, as the product of the binding of
a highly reactive molecule, dopaquinone, to cysteine. 5SCD
has been shown to be detectable in the serum and in urine of
melanomapatientsandtocorrelatewithdiseaseprogression.
In progressive patients it has been previously published
that 5SCD levels increased signiﬁcantly earlier than clinical
signs. A comparative report has stated that together with
LDH and S100B, 5SCD was an interesting biomarker even
if the authors of this report concluded that S100B could
be regarded as the most sensitive of the three markers.
Because of the eﬀect of UV exposure on melanin pigment
pathways the use of this 5SCD as a biomarker may be limited
in Caucasians, while its use in Japan is more extensive.
Moreover,patientswithamelanoticmetastasisusuallydonot
have increased serum levels of 5SCD.
3,4-dihydroxyphenylalanine(L-dopa)istheﬁrstmetabo-
lite involved in melanogenesis and its plasma levels have
been correlated with melanoma progression and tumor
burden, as well as the plasma L-dopa/L-Tyrosine ratio whichDermatology Research and Practice 5
represents an index of tyrosinase and tyrosine hydroxylase
activity. Stoitchkov et al. have shown that this latter ratio
has a predictive value, especially in stage III patients, and
advocated the simultaneous use of several biomarkers.
2.2.5.MatrixMetalloproteinases(MMPs). MMPsareafamily
of 24 structurally related endopeptidases. Theses zinc-de-
pendentenzymesaredeﬁnedbytheirownsubstratesandcan
lyse components of the ECM (for instance type IV collagen,
which is a major component of basement membrane by
gelatinases such as MMP-2 and MMP-9) and play a role
in angiogenesis and turnover of the ECM. MMP may also
cleave other molecules such as other proteinases, protein-
ase inhibitors, growth factors, adhesion molecules and in
consequence modulate the inﬂammatory reaction, growth
processes, tumor invasion, and metastasis.
A balance between MMP and tissue inhibitors metallo-
proteinases (TIMP) can be broken by an upregulation of
MMPs or a downregulation of TIMPs as this can be shown
in the acquisition of a malignant phenotype.
Another important role, angiogenesis, has been attrib-
uted to MMPs, and this could aﬀord a possible therapeutic
target.Batimastat(BB-94,asynthetic broadspectrummetal-
loproteinaseinhibitor)forinstancehasbeenshowntoinhibit
angiogenesis of liver metastases in mouse models.
MMP expression has been reported during melanoma
progression, and high serum levels of MMPs, namely, MMP-
1 and MMP-3, have been correlated with poor survival.
2.2.6. Cytokines, Chemokines, and Their Receptors. Che-
mokines are small signalling polypeptides that can bind
to and activate G protein-coupled receptors, a family of
seven transmembrane molecules. Multiple roles have been
attributedtochemokines,andthesemoleculesareimplicated
in the transformation and metastasis processes. Pattern
expression of chemokines and their receptors could explain
organ-speciﬁc metastasis.
Melanoma cells have been shown to express the chemok-
ine CXCL8, also known as interleukin-8 (IL-8), and a report
has established that high serum levels of IL-8 are associated
with tumor burden and poor prognosis. This might be
an interesting approach since in vivo studies have already
demonstratedthatanti-IL8humanizedantibodies areableto
decrease tumor growth and angiogenesis.
VeryrecentlyanAmericanteaminvestigated29cytokines
simultaneously (chemokines, angiogenic factors, growth
factors, soluble receptors) with a high-throughput multiplex
immunobead assay technology (Luminex Corp., Austin, Tex,
USA) in the sera of 179 patients with high-risk melanoma
and 378 healthy individuals. They were able to deﬁne a
speciﬁc serum cytokine proﬁle in the patients compared to
healthy individuals—higher serum concentrations of inter-
leukin (IL)-1alpha, IL-1beta, IL-6, IL-8, IL-12p40, IL-13,
granulocyte colony-stimulating factor, monocyte chemoat-
tractant protein 1 (MCP-1), macrophage inﬂammatory
protein (MIP)-1alpha, MIP-1beta, IFN-alpha, tumor necro-
sis factor (TNF)-alpha, epidermal growth factor, vascular
endothelial growth factor (VEGF), and TNF receptor II.
Moreover they showed that IFN-alpha2b therapy resulted
in a signiﬁcant decrease of serum levels of immunosup-
pressive and tumor angiogenic/growth stimulatory factors
and increased levels of antiangiogenic IFN-gamma inducible
protein 10 (IP-10) and IFN-alpha. Finally they established
a predictive value to the pretreatment levels of proinﬂam-
matory cytokines IL-1beta, IL-1alpha, IL-6, TNF-alpha, and
chemokines MIP-1alpha and MIP-1beta which were found
to be signiﬁcantly higher in the serum of patients with longer
RFS values [12]. Both IL-10 and soluble IL-2 receptors have
been correlated to poor outcome [13, 14].
2.2.7. Growth Factors and Angiogenesis Factor
Vascular Endothelial Growth Factor (VEGF). Angiogenesis
is an important step in tumor growth since it allows the
delivery of oxygen andsubstrates.This process is the resultof
complex interactions between proangiogenic and antiangio-
genic factors released by either tumor cells, native endothe-
lial, epithelial, mesothelial cells and leucocytes. VEGF has
been described as a potent mitogen of endothelial cells
and a chemotactic factor also for monocytes and Tumor-
Associated Macrophages (TAM’s) and plays a key regulatory
role during neoangiogenesis. Moreover, this growth factor is
a vasopermeability stimulant and was formerly known as the
Vascular Permeability Factor (VPF). Its expression has been
correlated with tumor progression and prognosis and can be
increased by hypoxic conditions.
Various VEGFs have been discovered and referred as
VEGF-2, VEGF-3,.... Very recently, a tem has reported lower
serum of VEGF-C levels in metastatic patients with skin/
subcutaneous metastasis compared to metastatic patients
with other distant sites [15]. In another study, VEGF serum
level was not considered as in independent prognostic factor
in multivariate analysis [16].
Very recently, a team has reported lower serum VEGF-C
levels in metastatic patients with skin/subcutaneous metas-
tasis compared to metastatic patients with other distant sites.
2.3. Others: Cell Surface and Adhesion Molecules
2.3.1. Integrins. Integrins are cell components which assure
adhesion to the other cells, the ECM, or to other proteins,
as serum proteins. Other important roles can be played by
integrins as mediation of information between extra- and
intracellular space, angiogenesis.
Integrins are heterodimeric cell adhesion receptors com-
posedoftwosubunits,αandβ.Onthebasisoftheircommon
subunit, integrin heterodimers can be subdivided into αv, β1
and β2 integrins. The main integrins involved in melanoma
progression include αvβ3 (receptor for vitronectin and
ﬁbronectin), α2β1( c o l l a g e n ) ,α4β1 (ﬁbronectin), and α6β1
(laminin).
Somereportshaveshownthatincreasedserumlevelsofβ
integrins have been associated with shorter survival. Clinical
impact of this has yet to be deﬁned.
2.3.2. CD44. CD44 is a cell surface transmembrane gly-
coprotein, originally described as a homing receptor for6 Dermatology Research and Practice
lymphocytes. In the literature, this protein is described
to play a role in tumor invasion and metastatic process.
Multiple isoforms of CD44 are generated by alternative
splicing of transcripts of its gene. CD44 is an important
cell surface receptor for hyaluronan, and its downregulation
5CD44H, loss of CD44v3 expression has been correlated
with poor outcome by some but not conﬁrmed. Moreover
serum level studies have also been conducted, which did not
show any signiﬁcance in deﬁning the prognosis of melanoma
patients.
2.3.3. ICAM-1. ICAM-1 is an intercellular adhesion mole-
cule which can be found in the cell membranes of leukocytes
and endothelial cells. ICAM-1 is a ligand for LFA-1 (lym-
phocytes function-associated antigen-1, integrin family) of
Tcells, Bcells, macrophages, and neutrophils. Migration of
leukocytes is facilitated by ICAM-1/LFA-1 binding. Com-
parative measurements of serum levels of ICAM-1 and 5-
S-CD have concluded that the level of 5-S-CD is a better
marker for disease progression in melanotic melanoma,
and another study showed that sICAM-1 was increased in
metastatic patients but without independent prognostic
value in multivariate analysis [17].
3. Discussion
Cancer is a major cause of morbidity and mortality in our
society. It has exacted a tremendous price and has had
manydevastatingeﬀects.Inparticular,therisingincidenceof
cutaneousmelanomainwesternpopulationisamajorhealth
problem.
Melanoma growth and progression are well deﬁned in
their clinical and histopathological patterns. The prognosis
of CMM is strongly related to the stage at which it is
diagnosed; with early diagnosis, a high proportion of lesions
present a good prognosis.
I fd i a g n o s e dl a t e ,m e l a n o m ac a nb eav e r ya g g r e s s i v e
malignancy. Moreover, melanoma may sometimes exhibit
unpredictable clinical behaviour: the thickness of the pri-
mary lesion (Breslow index) is the most important prognos-
tic factor but patients with thick melanoma (Breslow index
> 4mm) can be free of disease and some patients with thin
melanoma (Breslow index < 1mm) can die of their disease.
Current therapies have limited eﬀectiveness, and surgery
remains the mainstay of the treatment. Better treatments
are certainly needed: the treatment results of advanced
melanoma patients yields poor or even absence of survival
beneﬁt. Only a few of them will get a beneﬁt from their
systemic treatment: survival of AJCC stage IV melanoma
patientswithvisceral/brainmetastasescanbeestimatedto6–
9 months. These poor therapeutic responses may be, at least
in part, due to inadequate treatment or inclusion of patients
in therapeutic protocols, linked to inappropriate staging.
In the past, the only prognostic factor used in melanoma
patients was limited to histology (tumor thickness) and the
localization of the primary tumor. These parameters remain
important but have been further complemented by many
clinical, pathological, and biological prognostic factors, par-
ticularly in advanced melanoma patients. Recently the use of
serum markers, isolated or combined, has been suggested in
order to reﬁne the prognosis of a patient, to ensure adequate
followup, and to predict the possible beneﬁt from a therapy.
Severalmelanoma-speciﬁcornonspeciﬁcbiomarkerscanbe
found in the serum of advanced patients, and in most cases,
these markers are directly correlated with tumor burden.
Amongallthesebiomarkers,S100Bemergesasaproteinwith
an independent prognostic value in advanced melanoma,
more speciﬁc and sensitive than LDH, as illustrated by some
studies, but not yet ideal.
Because biomarkers are a useful way to understand the
biological diversity of melanoma, new biomarkers should be
deﬁned and further investigations should be carried out.
This biomarker research is important since it could
improve patient monitoring, early detection, and treatment
of secondary lesions and open new perspectives for targeted
therapies. The multiple molecular modiﬁcations underly-
ing melanoma progression are currently being intensely
investigated. Nowadays there is a wealth of data generated
by proteomic and genomic approaches, which is growing
daily. Thesetechniquesallowthedetermination of molecular
proﬁling of individual tumors and the study of expression
of thousands of genes in order to isolate genes or family
of genes of interest. It is important to recall that because
of posttranslational modiﬁcations an activated gene does
not mean a bioactive protein. These techniques give the
possibility of classifying melanomas based on their complex
biological diversity, and this will have surely a direct impact
on the deﬁnition of new biomarkers and on their large scale
studies.
4. Conclusions
In melanoma patients, still more than other diseases, there is
a need for careful followup, and the question arises whether
biomarkers can be useful in daily practice. So far serum
tumor markers, speciﬁc for melanoma, have not routinely
been used. Despite the fact that LDH is the only serum
marker which have been included in the AJCC classiﬁcation,
wedaretothinkthatS100Bappearstobeapromisingprotein
which oﬀers a reliable prognostic value in AJCC stage III and
IV patients.
To a lesser extent because of ill-deﬁned or poorer sensi-
tivity/speciﬁcity,CRP,MIA,andGal-3canalsobeconsidered
as interesting biomarkers. LDH and CRP maintain their
important place in this ﬁeld because of their easy availability.
Other molecules such as melanin metabolites, cytokines,
metalloproteinase, and adhesion proteins might be useful,
butinanycase,theirclinicalsigniﬁcanceshouldbecompared
in prospective trials to other melanoma markers described.
Clinical research should probably now focus on combi-
nation of these molecules and distinguish their prognostic
and predictive value.
Proteomicpatternstudyandgenomicresearchwillsurely
yield evidence in the next decade leading to more well-
deﬁned serum indicators of melanoma progression that can
be used for early diagnosis and/or improved and tailored
cancer therapy.Dermatology Research and Practice 7
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